Zydus Lifesciences reported consolidated revenue of ₹6,123.2 crore for the September quarter, a 17% year-on-year increase that surpassed analyst expectations, while net profit grew 38% to ₹1,258.6 crore. EBITDA rose 38% to ₹2,015.8 crore, lifting the margin by 500 basis points to 32.9%. The U.S. market contributed 45% of revenue at ₹2,743.7 crore, up 14% year-on-year, with Sitagliptin offsetting lower Revlimid sales, while the India formulations segment delivered 8% growth to ₹1,593 crore. International formulations revenue advanced 39% to ₹751.3 crore on broad-based demand across emerging markets and Europe. Strategic acquisitions—including UK-based Comfort Click in wellness and a completed 100% buyout of French medtech firm Amplitude Surgical—support the company’s diversification strategy. Management highlighted the strength of its multi-geography, multi-vertical model and its execution capabilities. The firm’s board has now cleared a sizeable capital raise to further its growth agenda.

Total raised

$564M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025